Merck: confirms acquisition of Verona Pharma

Published: 2025-07-09 08:23:23 ET MRK

Published on 07/09/2025 at 08:23

Merck confirms the acquisition of Verona Pharma, a biopharmaceutical company specializing in respiratory diseases.Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each representing eight shares of Verona Pharma common stock, for a total transaction value of approximately $10bn.This acquisition will add Ohtuvayre (ensifentrine) to Merck's portfolio. The US Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. This acquisition of Verona Pharma reflects our commitment to providing innovative treatments to patients and our ability to execute our science- and value-driven commercial development strategy, said Robert M. Davis, chairman and CEO of Merck.The transaction was unanimously approved by the boards of directors of Merck and Verona Pharma. The transaction is expected to close in Q4 2025.Copyright (c) 2025 CercleFinance.com - All rights reserved.